Reply To: Anti-MAG treatment update
January 23, 2018 at 9:38 am
Hello everybody
This information to follow
The Obinutuzumab (GAZYVA), a Potent Anti-B Cell Agent, in the Treatment of Rituximab-Unresponsive IgM Anti-Myelin-Associated-Glycoprotein (MAG)-Mediated-Neuropathy will be submitte to the American Academy of Neurology annual meeting April 2018
Take care
Matou